Literature DB >> 19039679

Psychological insulin resistance: patient beliefs and implications for diabetes management.

Meryl Brod1, Jens Harald Kongsø, Suzanne Lessard, Torsten L Christensen.   

Abstract

PURPOSE: To define and understand patient psychological insulin resistance (PIR) and its impact on diabetes management.
METHODS: Systematic literature review of peer-refereed journals using the MEDLINE database, including all articles in English from 1985 to 2007. The population included patients with type 1 and type 2 diabetes, insulin naïve, and those currently using insulin. A total of 116 articles were reviewed.
RESULTS: PIR is impacted by patients' beliefs and knowledge about diabetes and insulin, negative self-perceptions and attitudinal barriers, the fear of side effects and complications from insulin use, as well as lifestyle adaptations, restrictions required by insulin use, and social stigma. These etiological influences, both independently and in combination, constitute a patient's PIR and may result in the reluctance of patients to both initiate and intensify treatment, leading to delayed treatment initiation and compromised glucose control.
CONCLUSIONS: PIR is complex and multifaceted. It plays an important, although often ignored, role in diabetes management. Assisting health care professionals in better understanding PIR from the patient's perspective should result in improved treatment outcomes. By tailoring treatments to patients' PIR, clinicians may be better able to help their patients begin insulin treatment sooner and improve compliance, thus facilitating target glycemic control.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19039679     DOI: 10.1007/s11136-008-9419-1

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  86 in total

1.  Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

2.  Willingness to pay for inhaled insulin: a contingent valuation approach.

Authors:  Hamid Sadri; Linda D MacKeigan; Lawrence A Leiter; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  First approved inhaled insulin therapy for diabetes mellitus.

Authors:  Rucha Jani; Curtis Triplitt; Charles Reasner; Ralph A Defronzo
Journal:  Expert Opin Drug Deliv       Date:  2007-01       Impact factor: 6.648

4.  Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.

Authors:  Won Chan Lee; Sanjeev Balu; David Cobden; Ashish V Joshi; Chris L Pashos
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

5.  The influence of treatment modality and ethnicity on attitudes in type 2 diabetes.

Authors:  J T Fitzgerald; L D Gruppen; R M Anderson; M M Funnell; S J Jacober; G Grunberger; L C Aman
Journal:  Diabetes Care       Date:  2000-03       Impact factor: 19.112

6.  Determinants of injecting insulin in elderly patients with type II diabetes mellitus.

Authors:  B H Wolffenbuttel; C H Drossaert; A P Visser
Journal:  Patient Educ Couns       Date:  1993-12-31

Review 7.  AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes.

Authors:  Julio Rosenstock; Douglas Muchmore; Diana Swanson; Jennifer Schmitke
Journal:  Expert Rev Med Devices       Date:  2007-09       Impact factor: 3.166

Review 8.  Does insulin detemir have a role in reducing risk of insulin-associated weight gain?

Authors:  K Hermansen; M Davies
Journal:  Diabetes Obes Metab       Date:  2007-05       Impact factor: 6.577

9.  U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes       Date:  1995-11       Impact factor: 9.461

Review 10.  Medication taking and diabetes: a systematic review of the literature.

Authors:  Peggy Soule Odegard; Kam Capoccia
Journal:  Diabetes Educ       Date:  2007 Nov-Dec       Impact factor: 2.140

View more
  60 in total

1.  Older adults' fears about diabetes: using common sense models of disease to understand fear origins and implications for self-management.

Authors:  Sara A Quandt; Teresa Reynolds; Christine Chapman; Ronny A Bell; Joseph G Grzywacz; Edward H Ip; Julienne K Kirk; Thomas A Arcury
Journal:  J Appl Gerontol       Date:  2013-10

2.  Reliability and validity of the Norwegian child and parent versions of the DISABKIDS Chronic Generic Module (DCGM-37) and Diabetes-Specific Module (DSM-10).

Authors:  Dag Helge Frøisland; Trond Markestad; Tore Wentzel-Larsen; Torild Skrivarhaug; Knut Dahl-Jørgensen; Marit Graue
Journal:  Health Qual Life Outcomes       Date:  2012-02-02       Impact factor: 3.186

3.  Patient and family expectations of beta-cell replacement therapies in type 1 diabetes.

Authors:  Akitsu Kawabe; Shinichi Matsumoto; Masayuki Shimoda
Journal:  Islets       Date:  2018-08-17       Impact factor: 2.694

Review 4.  Assessing Psychological Insulin Resistance in Type 2 Diabetes: a Critical Comparison of Measures.

Authors:  E Holmes-Truscott; F Pouwer; J Speight
Journal:  Curr Diab Rep       Date:  2017-07       Impact factor: 4.810

5.  Evolving trends in insulin delivery in pursuit of improvements in diabetes management.

Authors:  Firas Akhrass; Nancy Skinner; Kimberly Boswell; Luther B Travis
Journal:  Am Health Drug Benefits       Date:  2010-03

6.  A Behavioral Perspective of Therapeutic Inertia: A Look at the Transition to Insulin Therapy.

Authors:  Susan J Guzman
Journal:  Diabetes Spectr       Date:  2020-02

7.  Mindfulness-Based Stress Reduction and Diabetes.

Authors:  Robin R Whitebird; Mary Jo Kreitzer; Patrick J O'Connor
Journal:  Diabetes Spectr       Date:  2009-09-21

8.  Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment.

Authors:  Longyi Zeng; Hongyun Lu; Hongrong Deng; Panwei Mu; Xiaofeng Li; Manman Wang
Journal:  Diabetes Technol Ther       Date:  2011-08-30       Impact factor: 6.118

Review 9.  Social stigma in diabetes : a framework to understand a growing problem for an increasing epidemic.

Authors:  Jasmin Schabert; Jessica L Browne; Kylie Mosely; Jane Speight
Journal:  Patient       Date:  2013       Impact factor: 3.883

10.  Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors.

Authors:  Meryl Brod; Paul Valensi; Joseph A Shaban; Don M Bushnell; Torsten L Christensen
Journal:  Qual Life Res       Date:  2010-07-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.